The European Medicines Agency came to what it called a clear conclusion that the vaccine's benefits in protecting people from coronavirus-related death or hospitalisation outweighed the possible risks.Still, EMA said a link between rare events of blood clots in the brain and the shot could not be definitively ruled out and that it will continue its scrutiny, along with the British Medicines and Healthcare products Regulatory Agency .
After the EMA move, others also sought to reinforce confidence in AstraZeneca's vaccine, which is seen globally as an important asset due to its relatively easy storage and transport requirements and inexpensive price, compared to mRNA vaccines made by Pfizer and Moderna.
Italian Prime Minister Mario Draghi said Italy would follow suit, echoing sentiments from Cyprus, Latvia and Lithuania.Britain's MHRA is investigating five cases of the rare brain blood clot that had been reported out of 11 million shots administered in the UK.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.